NEW YORK — ImiDomics said on Monday that it has partnered with drug developer Gossamer Bio on the discovery and development of new treatments for immune-mediated inflammatory diseases (IMID), beginning with inflammatory bowel disease.
ImiDomics has developed a platform that analyzes clinical and molecular data derived from an immune-mediated inflammatory disease biobank at Vall d’Hebron University Hospital in Spain to generate insights into disease biology.